Overview
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sheba Medical CenterTreatments:
Imatinib Mesylate
Interferons
Criteria
Inclusion Criteria:- Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of
imatinib therapy.
Exclusion Criteria:
- Patients in imatinib study
- Patients with a history of intolerability to interferon.
- Patients with less than CCR or less than one year of imatinib therapy.